Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Iovance Biotherapeutics Inc (IOVA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,166,319
  • Shares Outstanding, K 123,420
  • Annual Sales, $ 0 K
  • Annual Income, $ -123,580 K
  • 60-Month Beta 1.92
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.52

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.29
  • Number of Estimates 6
  • High Estimate -0.18
  • Low Estimate -0.37
  • Prior Year -0.31
  • Growth Rate Est. (year over year) +6.45%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.21 +3.69%
on 03/25/19
11.36 -15.93%
on 03/05/19
-0.90 (-8.61%)
since 02/26/19
3-Month
8.26 +15.62%
on 01/24/19
11.36 -15.93%
on 03/05/19
+0.72 (+8.15%)
since 12/26/18
52-Week
7.26 +31.54%
on 12/21/18
18.25 -47.67%
on 08/31/18
-8.35 (-46.65%)
since 03/26/18

Most Recent Stories

More News
Iovance Biotherapeutics to Present at Upcoming Investor Conferences in March

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that company management...

IOVA : 9.55 (+1.06%)
Iovance Biotherapeutics Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Corporate Update

- Patient Enrollment Commenced in the Registrational Cohort 4 in Study of Lifileucel in Advanced Melanoma -

IOVA : 9.55 (+1.06%)
Iovance Biotherapeutics was Granted Fast Track Designation for LN-145 for Cervical Cancer

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that the U.S. Food...

IOVA : 9.55 (+1.06%)
Iovance Biotherapeutics to Host Fourth Quarter and Year-End 2018 Financial Results Conference Call and Webcast on Wednesday, February 27, 2019

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will report...

IOVA : 9.55 (+1.06%)
Iovance Biotherapeutics to Present at Upcoming Investor and Medical Conferences

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that the company will...

IOVA : 9.55 (+1.06%)
Iovance Biotherapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that the company will...

IOVA : 9.55 (+1.06%)
JPM : 99.92 (+1.00%)
Iovance Biotherapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update

- Company to Host Conference Call at 4:30pm ET Today -

IOVA : 9.55 (+1.06%)
Iovance Biotherapeutics to Host First Quarter 2018 Financial Results Conference Call and Webcast on Thursday, May 10, 2018

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will report...

IOVA : 9.55 (+1.06%)
Iovance Biotherapeutics to Present at Two Upcoming Investor Conferences in May

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that company management...

IOVA : 9.55 (+1.06%)
DB : 8.28 (+1.35%)
Technical Perspectives on Biotech Stocks -- Intrexon, Iovance Biotherapeutics, Jaguar Health, and Jazz Pharma

WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on XON, IOVA, JAGX, and JAZZ which can be accessed for free by signing up to www.wallstequities.com/registration....

IOVA : 9.55 (+1.06%)
JAZZ : 136.54 (-0.28%)
XON : 5.30 (+6.21%)
JAGX : 0.24 (-11.21%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade IOVA with:

Business Summary

Iovance Biotherapeutics, Inc. is a biopharmaceutical company. It focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. Iovance Biotherapeutics Inc., formerly known as Lion Biotechnologies...

See More

Key Turning Points

2nd Resistance Point 9.88
1st Resistance Point 9.66
Last Price 9.55
1st Support Level 9.22
2nd Support Level 9.00

See More

52-Week High 18.25
Fibonacci 61.8% 14.05
Fibonacci 50% 12.76
Fibonacci 38.2% 11.46
Last Price 9.55
52-Week Low 7.26

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar